Abstract
One hundred and forty one years have passed since Armand Trousseau’s initial observation that venous thromboembolism (VTE) is a common manifestation of an underlying malignancy (1). Despite widespread recognition of this association and the availability of a multiple options for prevention and treatment of venous thrombosis, VTE remains a common cause of morbidity and mortality in cancer patients. The purpose of this chapter will be to review: (1) The epidemiology of VTE in cancer patients, (2) The pathogenesis of cancer-related thrombosis, (3) The prevention and treatment of VTE in the cancer patient, and (4) Special topics in VTE management including management of recurrent VTE and heparin-induced thrombocytopenia.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Trousseau A. Phlegmasia alba dolens. In: Trouuseau A, editor. Clinique Medicale de l’Hotel-Dieu de Paris. Paris: Balliere, 1865: 654–712.
Heit JA, Silverstein MD, Mohr DN. et al. 2000; Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 160:(6)809–815.
Blom JW, Doggen CJ, Osanto S, Rosendaal FR. 2005; Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 293:(6)715–722.
Deitcher SR. 2003; Cancer and thrombosis: mechanisms and treatment. J Thromb Thrombolysis. 16:(1–2)21–31.
Levitan N, Dowlati A, Remick SC. et al. 1999; Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 78:(5)285–291.
Blom JW, Vanderschoot JP, Oostindier MJ. et al. 2006; Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 4:(3)529–535.
Stein PD, Beemath A, Meyers FA. et al. 2006; Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 119:(1)60–68.
Khorana AA, Francis CW, Culakova E. et al. 2006; Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 24:(3)484–490.
Chew HK, Wun T, Harvey D. et al. 2006; Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 166:(4)458–464.
Ogren M, Bergqvist D, Wahlander K. et al. 2006; Trousseau’s syndrome - what is the evidence? A population-based autopsy study. Thromb Haemost. 95:(3)541–545.
Blom JW, Osanto S, Rosendaal FR. 2004; The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost. 2:(10)1760–1765.
Baron JA, Gridley G, Weiderpass E. et al. 1998; Venous thromboembolism and cancer. Lancet. 351:(9109)1077–1080.
Sorensen HT, Mellemkjaer L, Steffensen FH. et al. 1998; The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 338:(17)1169–1173.
Piccioli A, Lensing AW, Prins MH. et al. 2004; Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost. 2:(6)884–889.
Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. 2000; Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 343:(25)1846–1850.
Semeraro N, Colucci M. 1997; Tissue factor in health and disease. Thromb Haemost. 78:(1)759–764.
Rong Y, Post DE, Pieper RO. et al. 2005; PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res. 65:(4)1406–1413.
Hamada K, Kuratsu J, Saitoh Y. et al. 1996; Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer. 77:(9)1877–1883.
Wojtukiewicz MZ, Rucinska M, Zacharski LR. et al. 2001; Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb Haemost. 86:(6)1416–1420.
Gordon SG. 1992; Cancer cell procoagulants and their role in malignant disease. Semin Thromb Hemost. 18:(4)424–433.
Hettasch JM, Bandarenko N, Burchette JL. et al. 1996; Tissue transglutaminase expression in human breast cancer. Lab Invest. 75:(5)637–645.
Barbui T, Finazzi G, Falanga A. 1998; The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood. 91:(9)3093–3102.
Kwaan HC, Keer HN, Radosevich JA. et al. 1991; Components of the plasminogen-plasmin system in human tumor cell lines. Semin Thromb Hemost. 17:(3)175–182.
Falanga A, Rickles FR. 1999; Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost. 25:(2)173–182.
Nash GF, Walsh DC, Kakkar AK. 2001; The role of the coagulation system in tumour angiogenesis. Lancet Oncol. 2:(10)608–613.
Streiff MB, Segal J, Grossman SA. et al. 2004; ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer. 100:(8)1717–1723.
Jick H, Porter J. 1978; Thrombophlebitis of the lower extremities and ABO blood type. Arch Intern Med. 138:(10)1566–1567.
Talbot S, Wakley EJ, Ryrie D, Langman MJ. 1970; ABO blood groups and venous thromboembolic disease. Lancet. 1:(7659)1257–1259.
O’Donnell J, Laffan MA. 2001; The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med. 11:(4)343–351.
O’Donnell J, Mumford AD, Manning RA, Laffan M. 2000; Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost. 83:(1)10–13.
Kraaijenhagen RA, in’t Anker PS, Koopman MM. et al. 2000; High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost. 83:(1)5–9.
Kyrle PA, Minar E, Hirschl M. et al. 2000; High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 343:(7)457–462.
Ramacciotti E, Wolosker N, Puech-Leao P. et al. 2003; Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thromb Res. 109:(4)171–174.
Pihusch R, Danzl G, Scholz M. et al. 2002; Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer. 94:(12)3120–3126.
Abramson N, Costantino JP, Garber JE. et al. 2006; Effect of factor V Leiden and prothrombin G20210 → A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial J Natl Cancer Inst. 98:(13)904–910.
Beer JH, Haeberli A, Vogt A. et al. 2002; Coagulation markers predict survival in cancer patients. Thromb Haemost. 88:(5)745–749.
White RH, Zhou H, Romano PS. 2003; Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 90:(3)446–455.
Jhingran A, Eifel PJ. 2000; Perioperative and postoperative complications of intracavitary radiation for FIGO stage I-III carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 46:(5)1177–1183.
Holm T, Singnomklao T, Rutqvist LE, 1996; Cedermark B. Adjuvant preoperative radiotherapy in patients with rectal carcinoma. Adverse effects during long-term follow-up of two randomized trials. Cancer. 78:(5)968–976.
Silvani A, Salmaggi A, Eoli M. et al. 2003; Venous thromboembolism in malignant glioma patients treated by chemoradiotherapy. Neurol Sci. 24:(4)272.
Weitz IC, Israel VK, Waisman JR. et al. 2002; Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb Haemost. 88:(2)213–220.
Edwards RL, Klaus M, Matthews E. et al. 1990; Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. Am J Med. 89:(1)25–28.
Khorana AA, Francis CW, Culakova E, Lyman GH. 2005; Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 104:(12)2822–2829.
Levine MN, Gent M, Hirsh J. et al. 1988; The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 318:(7)404–407.
Goodnough LT, Saito H, Manni A. et al. 1984; Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer. 54:(7)1264–1268.
Saphner T, Tormey DC, Gray R. 1991; Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 9:(2)286–294.
Pritchard KI, Paterson AH, Paul NA. et al. 1996; Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol. 14:(10)2731–2737.
Bonneterre J, Buzdar A, Nabholtz JM. et al. 2001; Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 92:(9)2247–2258.
Weijl NI, Rutten MF, Zwinderman AH. et al. 2000; Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 18:(10)2169–2178.
Numico G, Garrone O, Dongiovanni V. et al. 2005; Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer. 103:(5)994–999.
Jacobson GM, Kamath RS, Smith BJ, Goodheart MJ. 2005; Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynecol Oncol. 96:(2)470–474.
Priest JR, Ramsay NK, Steinherz PG. et al. 1982; A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr. 100:(6)984–989.
Alberts SR, Bretscher M, Wiltsie JC. et al. 1999; Thrombosis related to the use of L-asparaginase in adults with acute lymphoblastic leukemia: a need to consider coagulation monitoring and clotting factor replacement. Leuk Lymphoma. 32:(5–6)489–496.
Priest JR, Ramsay NK, Bennett AJ. et al. 1982; The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia. J Pediatr. 100:(6)990–995.
Liebman HA, Wada JK, Patch MJ, McGehee W. 1982; Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase. Cancer. 50:(3)451–456.
Otten HM, Mathijssen J, ten Cate H. et al. 2004; Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med. 164:(2)190–194.
Edwards RL, Klaus M, Matthews E. et al. 1990; Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. Am J Med. 89:(1)25–28.
Zangari M, Anaissie E, Barlogie B. et al. 2001; Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 98:(5)1614–1615.
Rajkumar SV, Hayman S, Gertz MA. et al. 2002; Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 20:(21)4319–4323.
Zangari M, Siegel E, Barlogie B. et al. 2002; Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 100:(4)1168–1171.
Zangari M, Saghafifar F, Anaissie E. et al. 2002; Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 13:(3)187–192.
Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM. 2003; Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost. 1:(3)445–449.
Baz R, Li L, Kottke-Marchant K. et al. 2005; The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 80:(12)1568–1574.
Zangari M, Barlogie B, Anaissie E. et al. 2004; Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 126:(5)715–721.
Ikhlaque N, Seshadri V, Kathula S, Baumann MA. 2006; Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol. 81:(6)420–422.
Knight R, DeLap RJ, Zeldis JB. 2006; Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 354:(19)2079–2080.
Kabbinavar F, Hurwitz HI, Fehrenbacher L. et al. 2003; Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 21:(1)60–65.
Shah MA, Ilson D, Kelsen DP. 2005; Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol. 23:(11)2574–2576.
Kuenen BC, Rosen L, Smit EF. et al. 2002; Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol. 20:(6)1657–1667.
Brotman DJ, Girod JP, Posch A. et al. 2006; Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res. 118:(2)247–252.
Verso M, Agnelli G. 2003; Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol. 21:(19)3665–3675.
Wun T, Law L, Harvey D. et al. 2003; Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer. 98:(7)1514–1520.
Steurer M, Sudmeier I, Stauder R, Gastl G. 2003; Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. Br J Haematol. 121:(1)101–103.
Vansteenkiste J, Pirker R, Massuti B. et al. 2002; Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 94:(16)1211–1220.
Galli M, Elice F, Crippa C. et al. 2004; Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. Haematologica. 89:(9)1141–1142.
Feagan BG, Wong CJ, Kirkley A. et al. 2000; Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med. 133:(11)845–854.
Smith KJ, Bleyer AJ, Little WC, Sane DC. 2003; The cardiovascular effects of erythropoietin. Cardiovasc Res. 59:(3)538–548.
Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299(8):914–924.
Lin A, Ryu J, Harvey D. et al. 2006; Low-dose warfarin does not decrease the rate of thrombosis in patients with cervix and vulvo-vaginal cancer treated with chemotherapy, radiation, and erythropoeitin. Gynecol Oncol. 102:(1)98–102.
Bratzler DW, Raskob GE, Murray CK. et al. 1998; Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. Arch Intern Med. 158:(17)1909–1912.
Rahim SA, Panju A, Pai M, Ginsberg J. 2003; Venous thromboembolism prophylaxis in medical inpatients: a retrospective chart review. Thromb Res. 111:(4–5)215–219.
Goldhaber SZ, Tapson VF. 2004; A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 93:(2)259–262.
Kakkar AK, Levine M, Pinedo HM. et al. 2003; Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist. 8:(4)381–388.
Stein PD, Beemath A, Meyers FA. et al. 2006; Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 119:(1)60–68.
Kakkar AK, Williamson RC. 1999; Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost. 25:(2)239–243.
Mismetti P, Laporte S, Darmon JY. et al. 2001; Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 88:(7)913–930.
. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg. 1997;84(8):1099–1103.
McLeod RS, Geerts WH, Sniderman KW. et al. 2001; Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. Ann Surg. 233:(3)438–444.
Agnelli G, Bergqvist D, Cohen AT. et al. 2005; Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg. 92:(10)1212–1220.
Agnelli G, Bolis G, Capussotti L. et al. 2006; A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 243:(1)89–95.
Bergqvist D, Agnelli G, Cohen AT. et al. 2002; Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 346:(13)975–980.
Rasmussen MS, Jorgensen LN, Wille-Jorgensen P. et al. 2006; Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost. 4:(11)2384–2390.
Roderick P, Ferris G, Wilson K. et al. 2005; Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. Health Technol Assess. 9:(49)iii–x, 1.
Geerts WH, Heit JA, Clagett GP. et al. 2001; Prevention of venous thromboembolism. Chest. 119:(1 Suppl)132S–175S.
Comerota AJ, Katz ML, White JV. 1992; Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail? Am J Surg. 164:(3)265–268.
Cornwell EE, III, Chang D, Velmahos G. et al. 2002; Compliance with sequential compression device prophylaxis in at-risk trauma patients: a prospective analysis. Am Surg. 68:(5)470–473.
Agnelli G, Piovella F, Buoncristiani P. et al. 1998; Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med. 339:(2)80–85.
Ramos R, Salem BI, De Pawlikowski MP. et al. 1996; The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery. Chest. 109:(1)82–85.
Kroger K, Weiland D, Ose C. et al. 2006; Risk factors for venous thromboembolic events in cancer patients. Ann Oncol. 17:(2)297–303.
Mismetti P, Laporte-Simitsidis S, Tardy B. et al. 2000; Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost. 83:(1)14–19.
Samama MM, Cohen AT, Darmon JY. et al. 1999; A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 341:(11)793–800.
Lechler E, Schramm W, Flosbach CW. 1996; The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis. 26:(Suppl 2)49–56.
Kleber FX, Witt C, Vogel G. et al. 2003; Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J. 145:(4)614–621.
Leizorovicz A, Cohen AT, Turpie AG. et al. 2004; Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 110:(7)874–879.
Cohen AT, Davidson BL, Gallus AS. et al. 2006; Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 332:(7537)325–329.
Blom JW, Osanto S, Rosendaal FR. 2006; High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. Eur J Cancer. 42:(3)410–414.
Monreal M, Raventos A, Lerma R. et al. 1994; Pulmonary embolism in patients with upper extremity DVT associated to venous central lines--a prospective study. Thromb Haemost. 72:(4)548–550.
Bern MM, Lokich JJ, Wallach SR. et al. 1990; Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med. 112:(6)423–428.
Monreal M, Alastrue A, Rull M. et al. 1996; Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost. 75:(2)251–253.
Karthaus M, Kretzschmar A, Kroning H. et al. 2006; Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol. 17:(2)289–296.
Verso M, Agnelli G, Bertoglio S. et al. 2005; Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol. 23:(18)4057–4062.
Wells PS. 2005; The role of qualitative D-dimer assays, clinical probability, and noninvasive imaging tests for the diagnosis of deep vein thrombosis and pulmonary embolism. Semin Vasc Med. 5:(4)340–350.
Oudega R, Hoes AW, Moons KG. 2005; The Wells rule does not adequately rule out deep venous thrombosis in primary care patients. Ann Intern Med. 143:(2)100–107.
Lee AY, Julian JA, Levine MN. et al. 1999; Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis. Ann Intern Med. 131:(6)417–423.
Sohne M, Kruip MJ, Nijkeuter M. et al. 2006; Accuracy of clinical decision rule, D-dimer and spiral computed tomography in patients with malignancy, previous venous thromboembolism, COPD or heart failure and in older patients with suspected pulmonary embolism. J Thromb Haemost. 4:(5)1042–1046.
Buller HR, Agnelli G, Hull RD. et al. 2004; Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 126:(3 Suppl)401S–428S.
Segal JB, Bolger DT, Jenckes MW. et al. 2003; Outpatient therapy with low molecular weight heparin for the treatment of venous thromboembolism: a review of efficacy, safety, and costs. Am J Med. 115:(4)298–308.
Warkentin TE, Greinacher A. 2004; Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 126:(3 Suppl)311S–337S.
Kearon C, Ginsberg JS, Julian JA. et al. 2006; Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA. 296:(8)935–942.
Martel N, Lee J, Wells PS. 2005; Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 106:(8)2710–2715.
Kuo KH, Kovacs MJ. 2005; Fondaparinux: a potential new therapy for HIT. Hematology. 10:(4)271–275.
Warkentin TE, Maurer BT, Aster RH. Heparin-Induced Thrombocytopenia Associated with Fondaparinux. New Eng J Med. 2007;356(25):2653–2655.
Merli G, Spiro TE, Olsson CG. et al. 2001; Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 134:(3)191–202.
Crowther MA, Berry LR, Monagle PT, Chan AK. 2002; Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol. 116:(1)178–186.
Bijsterveld NR, Moons AH, Boekholdt SM. et al. 2002; Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 106:(20)2550–2554.
Ageno W, Grimwood R, Limbiati S. et al. 2005; Home-treatment of deep vein thrombosis in patients with cancer. Haematologica. 90:(2)220–224.
Siragusa S, Arcara C, Malato A. et al. 2005; Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients. Ann Oncol. 16:(Suppl 4)iv136–iv139.
Dager WE, King JH, Branch JM. et al. 2005; Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis. Ann Pharmacother. 39:(7–8)1182–1187.
Kovacs MJ, Anderson D, Morrow B. et al. 2000; Outpatient treatment of pulmonary embolism with dalteparin. Thromb Haemost. 83:(2)209–211.
Goldhaber SZ, Visani L, De Rosa M. 1999; Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 353:(9162)1386–1389.
Wicki J, Perrier A, Perneger TV. et al. 2000; Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost. 84:(4)548–552.
Kucher N, Rossi E, De Rosa M, Goldhaber SZ. 2005; Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mmHg or higher. Arch Intern Med. 165:(15)1777–1781.
Schoepf UJ, Kucher N, Kipfmueller F. et al. 2004; Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation. 110:(20)3276–3280.
O’Connell CL, Boswell WD, Duddalwar V. et al. 2006; Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol. 24:(30)4928–4932.
Konstantinides S, Geibel A, Heusel G. et al. 2002; Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 347:(15)1143–1150.
Comerota AJ, Aldridge SC. 1993; Thrombolytic therapy for deep venous thrombosis: a clinical review. Can J Surg. 36:(4)359–364.
Mewissen MW, Seabrook GR, Meissner MH. et al. 1999; Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology. 211:(1)39–49.
Kim HS, Patra A, Paxton BE. et al. 2006; Adjunctive percutaneous mechanical thrombectomy for lower-extremity deep vein thrombosis: clinical and economic outcomes. J Vasc Interv Radiol. 17:(7)1099–1104.
Hann CL, Streiff MB. 2005; The role of vena caval filters in the management of venous thromboembolism. Blood Rev. 19:(4)179–202.
Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005; 112:(3)416–422.
Linenberger ML. 2006; Catheter-related thrombosis: risks, diagnosis, and management. J Natl Compr Canc Netw. 4:(9)889–901.
Streiff MB. 2006; Long-term therapy of venous thromboembolism in cancer patients. J Natl Compr Canc Netw. 4:(9)903–910.
Ansell J, Hirsh J, Poller L. et al. 2004; The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 126:(3 Suppl)204S–233S.
Streiff MB, Segal JB, Tamariz LJ. et al. 2006; Duration of vitamin K antagonist therapy for venous thromboembolism: a systematic review of the literature. Am J Hematol. 81:(9)684–691.
Palareti G, Legnani C, Lee A. et al. 2000; A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost. 84:(5)805–810.
Prandoni P, Lensing AW, Piccioli A. et al. 2002; Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 100:(10)3484–3488.
Hutten BA, Prins MH, Gent M. et al. 2000; Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 18:(17)3078–3083.
Meyer G, Marjanovic Z, Valcke J. et al. 2002; Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 162:(15)1729–1735.
Deitcher SR, Kessler CM, Merli G. et al. 2006; Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 12:(4)389–396.
Hull RD, Pineo GF, Brant RF,. et al. 2006; Long-term low molecular weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med119:(12)1062–1072.
Lee AY, Levine MN, Baker RI. et al. 2003; Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 349:(2)146–153.
Aujesky D, Smith KJ, Cornuz J, Roberts MS. 2005; Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism. Thromb Haemost. 93:(3)592–599.
Bernardi E, Bagatella P, Frulla M. et al. 2001; Postthrombotic syndrome: incidence, prevention, and management. Semin Vasc Med. 1:(1)71–80.
Prandoni P, Villalta S, Bagatella P. et al. 1997; The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 82:(4)423–428.
Prandoni P, Lensing AW, Prins MH. et al. 2004; Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med. 141:(4)249–256.
Brandjes DP, Buller HR, Heijboer H. et al. 1997; Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet. 349:(9054)759–762.
Crowther MA, Ginsberg JS, Julian J. et al. 2003; A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 349:(12)1133–1138.
Luk C, Wells PS, Anderson D, Kovacs MJ. 2001; Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med. 111:(4)270–273.
Warkentin TE, Greinacher A. 2004; Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 126:(3 Suppl)311S–337S.
Sack GH, Jr., Levin J, Bell WR. 1977; Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore). 56:(1)1–37.
Merli G, Spiro TE, Olsson CG. et al. 2001; Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 134:(3)191–202.
Zacharski LR, Henderson WG, Rickles FR. et al. 1984; Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer. 53:(10)2046–2052.
Aisner J, Goutsou M, Maurer LH. et al. 1992; Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-disease small-cell lung cancer: a Cancer and Leukemia Group B pilot study. J Clin Oncol. 10:(8)1230–1236.
Maurer LH, Herndon JE, Hollis DR. et al. 1997; Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol. 15:(11)3378–3387.
Chahinian AP, Propert KJ, Ware JH. et al. 1989; A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol. 7:(8)993–1002.
Smorenburg SM, Van Noorden CJ. 2001; The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev. 53:(1)93–105.
Dolovich LR, Ginsberg JS, Douketis JD. et al. 2000; A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med. 160:(2)181–188.
Kakkar AK, Levine MN, Kadziola Z. et al. 2004; Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 22:(10)1944–1948.
Klerk CP, Smorenburg SM, Otten HM. et al. 2005; The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 23:(10)2130–2135.
Lee AY, Rickles FR, Julian JA. et al. 2005; Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 23:(10)2123–2129.
Altinbas M, Coskun HS, Er O. et al. 2004; A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2:(8)1266–1271.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science + Business Media, LLC
About this chapter
Cite this chapter
Streiff, M. (2009). Pathogenesis and Management of Venous Thromboembolism in Cancer Patients. In: Ettinger, D.S. (eds) Supportive Care in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-291-5_6
Download citation
DOI: https://doi.org/10.1007/978-1-59745-291-5_6
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-58829-941-3
Online ISBN: 978-1-59745-291-5
eBook Packages: MedicineMedicine (R0)